Y Intercept Hong Kong Ltd Makes New Investment in Ocugen, Inc. (NASDAQ:OCGN)

Y Intercept Hong Kong Ltd bought a new stake in Ocugen, Inc. (NASDAQ:OCGN) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 164,354 shares of the company’s stock, valued at approximately $132,000. Y Intercept Hong Kong Ltd owned 0.06% of Ocugen as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Rhumbline Advisers boosted its position in Ocugen by 12.9% during the 4th quarter. Rhumbline Advisers now owns 324,475 shares of the company’s stock valued at $261,000 after purchasing an additional 37,034 shares during the period. SG Americas Securities LLC lifted its stake in Ocugen by 72.7% in the fourth quarter. SG Americas Securities LLC now owns 152,176 shares of the company’s stock valued at $123,000 after buying an additional 64,080 shares during the last quarter. Franklin Resources Inc. bought a new stake in Ocugen in the third quarter valued at $142,000. Barclays PLC boosted its holdings in shares of Ocugen by 104.3% during the third quarter. Barclays PLC now owns 581,087 shares of the company’s stock valued at $577,000 after acquiring an additional 296,654 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Ocugen by 6.3% during the third quarter. Geode Capital Management LLC now owns 6,278,554 shares of the company’s stock worth $6,231,000 after acquiring an additional 373,555 shares during the last quarter. 10.27% of the stock is owned by institutional investors.

Ocugen Trading Down 2.8 %

NASDAQ:OCGN opened at $0.57 on Thursday. The stock has a market cap of $167.07 million, a price-to-earnings ratio of -3.19 and a beta of 3.88. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.58 and a current ratio of 2.58. Ocugen, Inc. has a 1 year low of $0.55 and a 1 year high of $2.11. The business has a fifty day moving average of $0.73 and a 200-day moving average of $0.91.

Ocugen (NASDAQ:OCGN) last announced its earnings results on Wednesday, March 5th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.05). Ocugen had a negative net margin of 532.51% and a negative return on equity of 154.75%. The firm had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. During the same quarter in the prior year, the firm posted ($0.03) EPS. Equities analysts predict that Ocugen, Inc. will post -0.2 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on OCGN. HC Wainwright lifted their price objective on shares of Ocugen from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Chardan Capital reaffirmed a “buy” rating and set a $6.00 price target on shares of Ocugen in a report on Thursday, February 13th.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.